These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 33164098)

  • 1. Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis.
    Goswami RP; Ray A; Chatterjee M; Mukherjee A; Sircar G; Ghosh P
    Rheumatology (Oxford); 2021 Feb; 60(2):557-567. PubMed ID: 33164098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
    J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab treatment for systemic sclerosis-associated interstitial lung disease: a case series of 13 patients.
    Morgan K; Woollard C; Beinart D; Host LV; Roddy J
    Intern Med J; 2023 Jul; 53(7):1147-1153. PubMed ID: 35670218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Yoshizaki-Ogawa A; Asano Y; Kashiwabara K; Oba K; Sato S
    J Dermatol; 2022 Jan; 49(1):179-183. PubMed ID: 34661314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.
    Daoussis D; Melissaropoulos K; Sakellaropoulos G; Antonopoulos I; Markatseli TE; Simopoulou T; Georgiou P; Andonopoulos AP; Drosos AA; Sakkas L; Liossis SN
    Semin Arthritis Rheum; 2017 Apr; 46(5):625-631. PubMed ID: 27839742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
    Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
    Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid decrease of serum surfactant protein-D levels predicts the reactivity of rituximab therapy in systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Asano Y; Oba K; Sato S
    J Dermatol; 2020 Jul; 47(7):796-800. PubMed ID: 32383266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab for connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis.
    Wang Y; Li L
    Int J Rheum Dis; 2023 Feb; 26(2):225-235. PubMed ID: 36378118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab and Cyclophosphamide in Antisynthetase Syndrome-related Interstitial Lung Disease: An Observational Retrospective Study.
    Langlois V; Gillibert A; Uzunhan Y; Chabi ML; Hachulla E; Landon-Cardinal O; Mariampillai K; Champtiaux N; Nunes H; Benveniste O; Hervier B
    J Rheumatol; 2020 Nov; 47(11):1678-1686. PubMed ID: 32173654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis.
    Borrirukwisitsak S; Tantayakom P; Katchamart W
    Clin Rheumatol; 2021 Jul; 40(7):2779-2789. PubMed ID: 33428098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in the Treatment of Interstitial Lung Disease Associated with Antisynthetase Syndrome: A Multicenter Retrospective Case Review.
    Doyle TJ; Dhillon N; Madan R; Cabral F; Fletcher EA; Koontz DC; Aggarwal R; Osorio JC; Rosas IO; Oddis CV; Dellaripa PF
    J Rheumatol; 2018 Jun; 45(6):841-850. PubMed ID: 29606668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effectiveness of cyclophosphamide and rituximab treatment in patients with systemic sclerosis-related interstitial lung diseases: a retrospective, observational cohort study.
    Yılmaz DD; Borekci S; Musellim B
    Clin Rheumatol; 2021 Oct; 40(10):4071-4079. PubMed ID: 34056665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of rituximab in connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis.
    Xing NS; Fan GZ; Yan F; Liu YP; Zhang R
    Int Immunopharmacol; 2021 Jun; 95():107524. PubMed ID: 33721757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre.
    Md Yusof MY; Kabia A; Darby M; Lettieri G; Beirne P; Vital EM; Dass S; Emery P
    Rheumatology (Oxford); 2017 Aug; 56(8):1348-1357. PubMed ID: 28444364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.
    Andersson H; Sem M; Lund MB; Aaløkken TM; Günther A; Walle-Hansen R; Garen T; Molberg Ø
    Rheumatology (Oxford); 2015 Aug; 54(8):1420-8. PubMed ID: 25740830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.
    Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Kazantzi A; Sirinian C; Karampetsou M; Yiannopoulos G; Andonopoulos AP
    Rheumatology (Oxford); 2010 Feb; 49(2):271-80. PubMed ID: 19447770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process.
    Roofeh D; Barratt SL; Wells AU; Kawano-Dourado L; Tashkin D; Strand V; Seibold J; Proudman S; Brown KK; Dellaripa PF; Doyle T; Leonard T; Matteson EL; Oddis CV; Solomon JJ; Sparks JA; Vassallo R; Maxwell L; Beaton D; Christensen R; Townsend W; Khanna D
    Semin Arthritis Rheum; 2021 Dec; 51(6):1331-1341. PubMed ID: 34493396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis.
    Showalter K; Hoffmann A; Rouleau G; Aaby D; Lee J; Richardson C; Dematte J; Agrawal R; Chang RW; Hinchcliff M
    J Rheumatol; 2018 Nov; 45(11):1572-1576. PubMed ID: 30275265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab in connective tissue disease-associated interstitial lung disease.
    Duarte AC; Cordeiro A; Fernandes BM; Bernardes M; Martins P; Cordeiro I; Santiago T; Seixas MI; Ribeiro AR; Santos MJ
    Clin Rheumatol; 2019 Jul; 38(7):2001-2009. PubMed ID: 31016581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of rituximab in connective tissue disorders related interstitial lung disease.
    Lepri G; Avouac J; Airò P; Anguita Santos F; Bellando-Randone S; Blagojevic J; Garcia Hernàndez F; Gonzalez Nieto JA; Guiducci S; Jordan S; Limaye V; Maurer B; Selva-O'Callaghan A; Riccieri V; Distler O; Matucci-Cerinic M; Allanore Y
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):181-185. PubMed ID: 27749242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.